A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase-Reference-Cited by-同舟云学术

A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase

Published:2016-08-10 Issue:21 Volume:122 Page:3336-3343
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Takahashi Koichi¹²,Kantarjian Hagop M.¹,Yang Yulong¹,Sasaki Koji¹,Jain Preetesh¹,DellaSala Sara¹,Ravandi Farhad¹,Kadia Tapan¹,Pemmaraju Naveen¹,Daver Naval¹,Borthakur Gautam¹,Garcia-Manero Guillermo¹,Jabbour Elias¹,Cortes Jorge E.¹

Affiliation:

1. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Department of Genomic Medicine; The University of Texas MD Anderson Cancer Center; Houston Texas

Funder

Bristol-Myers Squibb (BMS) (dasatinib) and Novartis (nilotinib)

University of Texas MD Anderson Cancer Center

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference21 articles.

1. Minute chromosome in human chronic granulocytic leukemia;Nowell;Science.,1960

2. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants;O'Hare;Cancer Res.,2005

3. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia;Kantarjian;N Engl J Med.,2010

4. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION);Kantarjian;Blood.,2012

5. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia;Saglio;N Engl J Med.,2010

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials;Leukemia;2024-01-29

2. Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia;Frontiers in Oncology;2022-10-06

3. South African study of blast phase chronic myeloid leukaemia: A poor prognostic outlook;African Journal of Laboratory Medicine;2022-05-31

4. Chromosomal Instability in Chronic Myeloid Leukemia: Mechanistic Insights and Effects;Cancers;2022-05-21

5. Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis;Cancer Medicine;2021-08-24